0001193125-23-102114.txt : 20230414 0001193125-23-102114.hdr.sgml : 20230414 20230414162005 ACCESSION NUMBER: 0001193125-23-102114 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 23821427 BUSINESS ADDRESS: STREET 1: 700 PARK OFFICES DRIVE STREET 2: SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: 700 PARK OFFICES DRIVE STREET 2: SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 10-K/A 1 d426596d10ka.htm 10-K/A 10-K/A
NC0001560241trueFY 0001560241 2022-01-01 2022-12-31 0001560241 2022-06-30 0001560241 2023-02-27 iso4217:USD xbrli:shares

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMM
IS
SION
Washington, D.C. 20549
 
 
FORM
10-K/A
(Amendment No.1)
 
 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM           TO
Commission File Number
001-38096
 
 
G1 THERAPEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
 
 
 
Delaware
  
26-3648180
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
700 Park Offices Drive, Suite 200
Research Triangle Park, NC 27709
(Address of principal executive offices including zip code)
Registrant’s telephone number, including area code: (919)
213-9835
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol
  
Name of each exchange
on which registered
Common Stock $.0001 par value   GTHX   The Nasdaq Stock Market
Securities registered pursuant to Section 12(g) of the Act: None
 
 
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☐    No  ☒
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes  ☐    No  ☒
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒    No  ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes  ☒    No  ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer   ☐    Accelerated filer   ☐
       
Non-accelerated filer   ☒    Smaller reporting company   ☒
       
Emerging growth company   ☐         
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b).  ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act). Yes  ☐    No  ☒
The aggregate market value of the voting and
non-voting
common equity held by
non-affiliates
of the Registrant as of June 30, 2022, the last business day of the Registrant’s most recently completed second fiscal quarter, was $209.0 million based on the closing price of the shares of common stock on The Nasdaq Stock Market on that date.
The number of shares of the Registrant’s Common Stock outstanding as of February 27, 2023 was 51,657,647.
 
Auditor Firm Id:    238    Auditor Name:    PricewaterhouseCoopers LLP    Auditor Location:    New York, NY, United States
Documents Incorporated by Reference
Portions of the Registrant’s Definitive Proxy Statement relating to the Annual Meeting of Stockholders, scheduled to be held on June 15, 2023, are incorporated by reference into Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31,
2022
.
 
 
 

Explanatory Note
G1 Therapeutics, Inc. is filing this Amendment No. 1 on Form
10-K/A
(“
Amendment No.
 1
”) to its Annual Report on Form
10-K
for the fiscal year ended December 31, 2022 filed with the Securities Exchange Commission (the “
SEC
”) on March 1, 2023 (the “
Original Form
10-K
”) solely for the purpose of filing a revised Consent of Independent Registered Public Accounting Firm on Exhibit 23.1 (the “
PwC Consent
”) to (i) include the conformed signature from PricewaterhouseCoopers LLP, the Company’s independent accountant, which due to an administrative error, was inadvertently omitted from the version of the PwC Consent attached to the Original Form
10-K
filed with the SEC and (ii) correct typographical errors. The signed PwC Consent was delivered prior to the filing of the Original Form
10-K.
Pursuant to Rule
12b-15
under the Securities Exchange Act of 1934, as amended, this
Amendment
No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been
included
in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation
S-K,
paragraphs 3, 4, and 5 of the certifications have been omitted.
Except as otherwise expressly noted herein, this Amendment No. 1 does not modify, amend, or update in any way the financial position, results of operations, cash flows, or other disclosure in, or exhibits to, the Original Form
10-K,
nor does it reflect events occurring after the filing of the Original Form
10-K.
Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form
10-K
and with the filings with the SEC subsequent to the Original Form
10-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    G1 THERAPEUTICS, INC.
Date: April 14, 2023     By:  

/s/ James Stillman Hanson

      James Stillman Hanson
      General Counsel
 EX-23.1 2 d426596dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-265832, 333-254705, 333-236229, 333-232106, 333-226701, and 333-218468) and Form S-3 (No. 333-257640) of G1 Therapeutics, Inc. of our report dated March 1, 2023 relating to the financial statements, which appears in this Form 10-K.

 

/s/ PricewaterhouseCoopers LLP
Raleigh, North Carolina
March 1, 2023

 

 EX-31.1 3 d426596dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John E. Bailey, Jr., certify that:

1. I have reviewed this Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K of G1 Therapeutics, Inc. originally filed on March 1, 2023; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: April 14, 2023              By:  

/s/ John E. Bailey, Jr.

      John E. Bailey, Jr.
      President and Chief Executive Officer
      (Principal Executive Officer)
 EX-31.2 4 d426596dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John W. Umstead V, certify that:

1. I have reviewed this Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K of G1 Therapeutics, Inc. originally filed on March 1, 2023; and

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: April 14, 2023              By:  

/s/ John W. Umstead V

      John W. Umstead V
      Chief Financial Officer
      (Principal Financial and Accounting Officer)
 EX-101.SCH 5 gthx-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 gthx-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 gthx-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 gthx-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 9 gthx-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Feb. 27, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-38096    
Entity Registrant Name G1 THERAPEUTICS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-3648180    
Entity Address, Address Line One 700 Park Offices Drive    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town Research Triangle Park    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27709    
City Area Code 919    
Local Phone Number 213-9835    
Title of 12(b) Security Common Stock $.0001 par value    
Trading Symbol GTHX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 209.0
Entity Common Stock, Shares Outstanding   51,657,647  
Documents Incorporated by Reference
Documents Incorporated by Reference
Portions of the Registrant’s Definitive Proxy Statement relating to the Annual Meeting of Stockholders, scheduled to be held on June 15, 2023, are incorporated by reference into Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31,
2022
.
    
Entity Central Index Key 0001560241    
Amendment Flag true    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Auditor Name PricewaterhouseCoopers LLP    
Auditor Firm ID 238    
Auditor Location New York, NY, United States    
Amendment Description G1 Therapeutics, Inc. is filing this Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities Exchange Commission (the “SEC”) on March 1, 2023 (the “Original Form 10-K”) solely for the purpose of filing a revised Consent of Independent Registered Public Accounting Firm on Exhibit 23.1 (the “PwC Consent”) to (i) include the conformed signature from PricewaterhouseCoopers LLP, the Company’s independent accountant, which due to an administrative error, was inadvertently omitted from the version of the PwC Consent attached to the Original Form 10-K filed with the SEC and (ii) correct typographical errors. The signed PwC Consent was delivered prior to the filing of the Original Form 10-K. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Except as otherwise expressly noted herein, this Amendment No. 1 does not modify, amend, or update in any way the financial position, results of operations, cash flows, or other disclosure in, or exhibits to, the Original Form 10-K, nor does it reflect events occurring after the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and with the filings with the SEC subsequent to the Original Form 10-K.    
XML 11 d426596d10ka_htm.xml IDEA: XBRL DOCUMENT 0001560241 2022-01-01 2022-12-31 0001560241 2022-06-30 0001560241 2023-02-27 iso4217:USD shares NC 0001560241 true FY 10-K/A true 2022-12-31 --12-31 2022 false 001-38096 G1 THERAPEUTICS, INC. DE 26-3648180 700 Park Offices Drive Suite 200 Research Triangle Park 27709 919 213-9835 Common Stock $.0001 par value GTHX NASDAQ No No Yes Yes Non-accelerated Filer true false true false 209000000 51657647 238 PricewaterhouseCoopers LLP New York, NY, United States <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Documents Incorporated by Reference </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Portions of the Registrant’s Definitive Proxy Statement relating to the Annual Meeting of Stockholders, scheduled to be held on June 15, 2023, are incorporated by reference into Part III of this report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, <div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div>.</div> G1 Therapeutics, Inc. is filing this Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities Exchange Commission (the “SEC”) on March 1, 2023 (the “Original Form 10-K”) solely for the purpose of filing a revised Consent of Independent Registered Public Accounting Firm on Exhibit 23.1 (the “PwC Consent”) to (i) include the conformed signature from PricewaterhouseCoopers LLP, the Company’s independent accountant, which due to an administrative error, was inadvertently omitted from the version of the PwC Consent attached to the Original Form 10-K filed with the SEC and (ii) correct typographical errors. The signed PwC Consent was delivered prior to the filing of the Original Form 10-K. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Except as otherwise expressly noted herein, this Amendment No. 1 does not modify, amend, or update in any way the financial position, results of operations, cash flows, or other disclosure in, or exhibits to, the Original Form 10-K, nor does it reflect events occurring after the filing of the Original Form 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Form 10-K and with the filings with the SEC subsequent to the Original Form 10-K. EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 3 39 1 false 0 0 false 2 false false R1.htm 1001 - Document - Cover Sheet http://www.G1.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince - d426596d10ka.htm 7 d426596d10ka.htm d426596dex231.htm d426596dex311.htm d426596dex312.htm gthx-20221231.xsd gthx-20221231_cal.xml gthx-20221231_def.xml gthx-20221231_lab.xml gthx-20221231_pre.xml http://xbrl.sec.gov/dei/2022 true true JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d426596d10ka.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 39 }, "contextCount": 3, "dts": { "calculationLink": { "local": [ "gthx-20221231_cal.xml" ] }, "definitionLink": { "local": [ "gthx-20221231_def.xml" ] }, "inline": { "local": [ "d426596d10ka.htm" ] }, "labelLink": { "local": [ "gthx-20221231_lab.xml" ] }, "presentationLink": { "local": [ "gthx-20221231_pre.xml" ] }, "schema": { "local": [ "gthx-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 40, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 39, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gthx", "nsuri": "http://www.G1.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d426596d10ka.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.G1.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d426596d10ka.htm", "contextRef": "P01_01_2022To12_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.G1.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" } }, "unitCount": 2 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001193125-23-102114-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-102114-xbrl.zip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end